Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market.
Under the terms of the deal, Novartis will pay USD 85 per share to the Medicines Company, a cholesterol drug developer, making the deal up to USD 9.7 Billion. The whole transaction will be completed by 2020.
Around 95 million US adults age 20 or older have total cholesterol levels higher than the normal levels i.e., 200mg/dL.
Inclisiran is a small interfering RNA therapy. The use of inclisiran for lowering down the blood cholesterol levels has still not been approved by any regulatory body. However, the results of ...
